Subcutaneous Ketamine in Depression: A Systematic Review.

Frontiers in Psychiatry
Vitor Breseghello CavenaghiRenério Fraguas

Abstract

Background: Ketamine has been shown to produce a rapid and robust antidepressant effect. Though numerous routes of administration have been studied, subcutaneous (SC) has proven to be a convenient and cost-effective route making its use particularly relevant in developing countries. Here we provide a systematic review covering the use of SC racemic ketamine and esketamine in depression, including its efficacy, safety and tolerability. Methods: A systematic literature search was carried out, from inception through March, 2021, using PubMed/MEDLINE, EMBASE and Web of Science, with no limits of language. After identifying 159 potentially relevant articles, 12 articles were selected after applying our inclusion/exclusion criteria. These comprised two randomized clinical trials, five case-reports and five retrospective studies. Given the small number of studies found and their heterogeneous nature, a meta-analysis was not considered appropriate. Here we provide a synthesis of these data including participant characteristics, dose range, efficacy, safety/ tolerability. Risk of bias was accessed using the Cochrane risk of bias tool. Results: SC Ketamine was administered to unipolar and bipolar patients a single or multiple doses, week...Continue Reading

References

Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Oct 1, 1995·Journal of Pain and Symptom Management·S MercadanteR Serretta
Feb 25, 2000·Biological Psychiatry·R M BermanJ H Krystal
Nov 3, 2005·Psychological Assessment·Alan Shafer
Aug 9, 2006·Archives of General Psychiatry·Carlos A ZarateHusseini K Manji
Aug 1, 1975·Neuroscience Letters·W V WeberS R Jawalekar
Jan 5, 2011·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Mihan J JavidAmir Keshvari
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Aug 3, 2012·The American Journal of Psychiatry·Cristina CusinMaurizio Fava
May 21, 2013·The International Journal of Neuropsychopharmacology·Diogo R LaraLuciano R Munari
Aug 29, 2013·The American Journal of Psychiatry·James W MurroughSanjay J Mathew
Jul 26, 2017·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Duncan GeorgeColleen K Loo
Aug 2, 2017·The Lancet. Psychiatry·Brooke ShortColleen K Loo
Nov 28, 2017·World Neurosurgery·Michael M McDowellRobert M Friedlander
Mar 30, 2019·The American Journal of Psychiatry·Jennifer L PhillipsPierre Blier
Apr 18, 2019·The Journal of Clinical Psychiatry·Joshua D RosenblatRoger S McIntyre
Feb 23, 2020·European Archives of Psychiatry and Clinical Neuroscience·Gustavo C LealLucas C Quarantini
Jul 9, 2020·Journal of Psychopharmacology·Lorena Catarina Del SantJair de Jesus Mari
Oct 6, 2020·Journal of Affective Disorders·Rodrigo Simonini DelfinoAcioly Luiz Tavares Lacerda
Oct 20, 2020·Revista de psiquiatrí́a y salud mental·Victor Augusto Rodovalho FavaHugo Cogo-Moreira
Nov 25, 2020·International Clinical Psychopharmacology·Fabio Lopes RochaDébora Pereira Thomaz

❮ Previous
Next ❯

Software Mentioned

Web
Cochrane risk

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.